Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 6, 2008 Steven Renaldi	McKesson Garners Generic Growth New products offer the generic-drug distributor profit potential in a competitive industry.
The Motley Fool January 2, 2004 Alyce Lomax	A Bitter Pill for Amerisource Veterans ditch Amerisource for rival; investors punish the entire pharmaceutical distribution industry.
The Motley Fool May 6, 2005 W.D. Crotty	McKesson's New Pep Pill The drug wholesaler reports strong fourth-quarter results as it moves to a fee-for-service model.
The Motley Fool March 26, 2007 Rich Duprey	Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note.
The Motley Fool November 7, 2007 Billy Fisher	Cardinal Has Its Wings Clipped Despite a healthy year-over-year pop of 15% in EPS from operations, much of the focus in the first-quarter was shifted to a weak performance by Cardinal's pharmaceutical services segment.
The Motley Fool December 1, 2005 Brian Gorman	Glaxo Follows the Biotechs The company's new focus on cancer drugs looks like a good move. Investors, take note.
The Motley Fool October 6, 2008 Brian Orelli	Cardinal Atones for Its Sins The drugmaker gets its licenses to distribute controlled substances reinstated.
The Motley Fool August 24, 2011 Brandon Glenn	Cardinal Health Sees Opportunity (but Faces Challenges) in Specialty Drugs Is Cardinal up for the challenge?
The Motley Fool November 9, 2005 W.D. Crotty	McKesson Fattens Its Margins The pharma distributor turns in an outstanding second quarter. Because McKesson is a broadly based supplier, it avoids the roller-coaster impact that specific drug successes and failures have on drug-developer stocks.
The Motley Fool September 30, 2008 Brian Orelli	Cardinal Health Clips Its Wings Does it make sense for the drug wholesaler to spin off its medical equipment business?
The Motley Fool January 21, 2005 Rich Duprey	Cardinal Back in the Nest Drug distributor and Japanese pharma Eisai come to agreement after all.
The Motley Fool April 7, 2011 Brandon Glenn	"Generic Wave" to Drive Cardinal Health's Profitability in Coming Years The generic wave could mean big money for Cardinal and top competitors.
The Motley Fool July 29, 2005 Richard Gibbons	Share Buybacks Aren't All Equal In the right circumstances -- when a company has excess capital and undervalued shares -- share repurchases are great for shareholders. But if the company is repurchasing overvalued shares, the buyback can actually be a sign of poor management.
The Motley Fool June 14, 2007 Nathan Parmelee	Target Releases Arrows Made of Money The retailer has done well by shareholders, and might do even better.
Pharmaceutical Executive July 3, 2007 Sarah Houlton	Global Report: Five-Year Survivor: European Edition The UK government's attitude seems to be that oncology treatments are hugely expensive -- and that too much of the National Health Service budget is vanishing into the pockets of drug companies. Will cancer networks fill the gap?
The Motley Fool September 21, 2011 Alex Dumortier	Dell: Compounding or Destroying Value? Dell's share buyback program looks like a good use of shareholder capital. In fact, I think it's worth adding Dell to your watchlist.
The Motley Fool October 27, 2011 Alex Dumortier	Don't Buy Into People's United's Buyback People's United's new buyback program doesn't mean you should buy.
The Motley Fool September 30, 2011 Alex Dumortier	Raytheon: Compounding or Destroying Value? With shares trading at 7.6 times its earnings-per-share estimate for the next 12 months, the share buyback program looks like a good use of shareholder capital at these prices.
The Motley Fool October 26, 2005 Stephen D. Simpson	Cardinal's Tweet More Sweet Changes at the giant manufacturer, distributor, and service provider in the health-care industry are working out well, but the stock price already reflects it.
The Motley Fool September 30, 2011 Alex Dumortier	Accenture: Creating or Destroying Value? With shares trading at 14.3 times its earnings-per-share estimate for the next 12 months, the share buyback program looks like a decent use of shareholder capital at these prices.
The Motley Fool August 21, 2007 Emil Lee	Are Buybacks Best? Without a doubt, share repurchases are one of the best uses of a company's excess capital. Here's why investors should get interested anytime they hear a company's planning to buy back its own shares.
The Motley Fool September 17, 2010 Luke Timmerman	Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders?
The Motley Fool June 2, 2009 Brian Orelli	ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies.
The Motley Fool September 28, 2011 Alex Dumortier	Lockheed Martin: Creating or Destroying Value? With shares trading at 9.3 times its earnings-per-share estimate for the next 12 months, the share buyback program looks like an acceptable use of shareholder capital at these prices.
BusinessWeek June 16, 2011 Langreth & Cortez	When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates.
The Motley Fool October 25, 2004 Tom Taulli	McKesson Gets Pain Relief Drug distributors would like to forget 2004. But this may mean bargains for investors.
The Motley Fool November 18, 2004 Charly Travers	A Glimpse of Bristol-Myers' Portfolio Late-stage drugs are crucial for a company beset with patent losses.
BusinessWeek August 30, 2004 Gene G. Marcial	PSS Is Really Delivering The Goods When David Smith took the CEO job at PSS World Medical in 2000, sales stood at $160 million. They've since rocketed to $1.35 billion. No wonder industry giants are eyeballing the company: They hope Smith will sell.
The Motley Fool December 7, 2006 Seth Jayson	Bad Advice on Buybacks The point of a buyback is not to "move" the stock -- not over the short term. The point of a buyback is to increase shareholder value in the long run by giving existing shareholders a bigger cut of future economic benefits.
The Motley Fool January 26, 2007 Billy Fisher	A Clean Bill of Health at Cardinal Good results and a key divestiture have this health care company rolling. Investors, take note.
The Motley Fool September 11, 2006 Ryan Fuhrmann	The Skinny on Share Buybacks Do buybacks enhance shareholder value? Many times, these plans can work out very well for investors. But does this really make a company more valuable? No, not really.
The Motley Fool August 5, 2005 Stephen D. Simpson	Can This Cardinal Sing? If Cardinal Health succeeds in its plans to return more capital to shareholders, this could become an interesting income play. This stock is worth keeping an eye on for the future.
The Motley Fool November 1, 2011 Alex Dumortier	Should IBM Be Buying Back Shares? At 13 times the next 12 months' estimated earnings, the shares don't look like any particular bargain.
BusinessWeek August 7, 2006 Arlene Weintraub	McKesson's Booster Shot McKesson Corp. holds the unenviable distinction of being one of the world's biggest yet least profitable companies. The problem: huge sales, tiny profits. High-margin tech products could help.
The Motley Fool October 28, 2004 Brian Gorman	Cardinal's Good News: No News The drug wholesaler took a major step toward rehabilitating itself with the release of its 10-K.
The Motley Fool May 27, 2011 Brian Orelli	What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool October 28, 2008 Rich Duprey	Don't Buy the Buyback Hype Are share buybacks little more than a tool for management to massage earnings? As for the benefit to individual shareholders, is it all it's cracked up to be?
The Motley Fool January 30, 2006 Brian Gorman	Cardinal Inches Higher The distribution is looking healthier, but Cardinal Health still has work to do. Investors, take note.
BusinessWeek June 21, 2004 Catherine Arnst	Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs.
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
The Motley Fool December 10, 2004 Brian Gorman	Cardinal Picks a Lilly Cardinal Health's deal with Lilly suggests the new fee-for-service model is gaining traction.
The Motley Fool May 31, 2011 Brian Orelli	Profit From This Growing Drug Trend Cancer drugs press on.
The Motley Fool June 13, 2006 Ryan Fuhrmann	Cardinal Looks to Deliver Cardinal Health has been through a tumultuous couple of years but appears to have weathered company-specific and industry storms. If the drug distributor can meet its long-term goals, then its stock should represent a long-term solid investment.
The Motley Fool August 3, 2006 Ryan Fuhrmann	Cardinal Distributes the Goods The drug wholesaler and distributor has to regain investor confidence and rebuild a track record in a changed industry. So far, so good for 2006. Let's see if any further information can be found once Cardinal submits its 10-K filing to the SEC.
The Motley Fool December 1, 2009 Selena Maranjian	Is Hewlett-Packard Crazy? Hewlett-Packard recently announced that its future is looking brighter and it's tripling its planned share repurchases, upping the limit to $12 billion worth of stock. Is it a good move?
The Motley Fool May 2, 2008 Steven Renaldi	Cardinal Health Gets Its Nest in Order Share price rises as investors hope the company is beginning to put some of its troubles behind it.
The Motley Fool February 8, 2011 Esterhuizen & Sellitti	Finding a Cure for Cancer: The Option Market's Favorite Ideas What cancer stocks are investors taking seriously?: Allos Therapeutics... China Medical Technologies... Delcath Systems... Myriad Genetics... ZIOPHARM...
Chemistry World July 2010 Hayley Birch	Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade.
Chemistry World June 22, 2011 Sarah Houlton	US Approves Cancer Drugs Twice as Fast as Europe Cancer drugs are, on average, approved nearly twice as fast in the US than they are in Europe.